Fasting Insulin and HOMA-IR: Reading Insulin Resistance Before Glucose

Insulin resistance precedes the rise in fasting glucose by several years. As long as the pancreas can secrete more insulin to compensate, glucose stays within range, and the metabolic imbalance progresses silently (PubMed).

Yet during a routine check-up, it is fasting glucose that your doctor comments on. If it falls within range, you leave reassured. This reading conflates two distinct things: the presence of a metabolic imbalance and the moment that imbalance becomes visible on the latest of all markers.

The signal exists earlier. It can be read in fasting insulin and in HOMA-IR.

Fasting glucose is a lagging indicator

Fasting glucose measures the final output of a regulatory system, not the effort that system expends to hold that output. As long as it compensates, the output looks normal, whatever the intensity of the underlying effort.

The Whitehall II study followed thousands of British civil servants and reconstructed the trajectory of their markers in the years preceding a type 2 diabetes diagnosis. The finding is clear: insulin sensitivity was already declining markedly five years before diagnosis, whereas fasting glucose only surged in the final three years, along a curve that accelerates sharply as the threshold approaches (PubMed).

This lag has a serious consequence. By the time fasting glucose finally crosses the limit of normal, a substantial part of the secretory capacity of the pancreatic beta cells is already lost (PubMed). The marker watched most closely is also the one that moves last.

Fasting insulin, the signal that rises first

If glucose holds, it is because insulin is climbing. Faced with cells that respond less well, the pancreas raises its output to achieve the same effect on glucose. This mechanism has a name: compensatory hyperinsulinemia (an excess of circulating insulin meant to keep glucose within range).

The relationship between insulin sensitivity and insulin secretion is hyperbolic. Kahn and colleagues showed that as sensitivity falls, secretion rises proportionally more, so that the product of the two initially remains constant (PubMed). This is the disposition index concept (the pancreas's capacity to match its secretion to the level of resistance). As long as that adjustment holds, glucose does not move. Fasting insulin, however, rises.

Fasting insulin is therefore a leading marker. On its own, it remains sensitive to the assay method: values are not perfectly comparable from one laboratory to another. It is by combining it with glucose that its reading gains robustness.

HOMA-IR: reading insulin and glucose together

In 1985, Matthews and colleagues proposed a simple model to estimate insulin resistance from two fasting measurements: insulin and glucose. This is HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) (PubMed). Its usual form fits on a single line:

HOMA-IR = fasting insulin (µU/mL) × fasting glucose (mmol/L) / 22.5

The model was validated against the euglycemic-hyperinsulinemic clamp, the reference method for measuring insulin sensitivity in the laboratory (PubMed). HOMA-IR does not match the precision of the clamp, but it requires only a fasting blood draw, which makes it usable at scale.

That simplicity comes with a caveat. Wallace, Levy, and Matthews detailed the uses and misuses of the model: HOMA-IR is reliable for comparing groups and following a trend, but its thresholds are not universal (PubMed). They depend on the population studied, on age, and on the insulin assay. The same number does not carry the same meaning everywhere.

Its prognostic value, on the other hand, is firmly established. In the Bruneck cohort, followed over a decade, HOMA-IR was among the few independent predictors of incident type 2 diabetes, alongside impaired fasting glucose and body mass index (PubMed). It carries information that glucose alone does not.

When insulin is not measured: the TyG index

Not every panel measures insulin. A surrogate marker has established itself for those situations: the TyG (triglyceride-glucose) index, calculated from fasting glucose and triglycerides, two parameters almost always present on a standard panel (PubMed).

Compared to the euglycemic-hyperinsulinemic clamp in nearly a hundred subjects, the TyG index proved strongly correlated with measured insulin sensitivity, with a sensitivity of 96.5% and a specificity of 85% for detecting insulin resistance (PubMed). It is not meant to replace a direct insulin measurement; it offers a useful estimate when one is unavailable.

Why the lag matters for longevity

The value of reading insulin resistance early is not limited to anticipating diabetes. Hyperinsulinemia and insulin resistance are, in themselves, associated with cardiovascular risk.

In the Quebec Cardiovascular Study, elevated fasting insulin predicted the occurrence of coronary heart disease independently of other risk factors. Risk rose by roughly 60% per standard deviation of insulin, after adjustment for blood pressure, triglycerides, and cholesterol (PubMed).

A meta-analysis of adults without diabetes confirmed the trend: the higher the HOMA-IR, the greater the risk of a cardiovascular event (PubMed). Insulin resistance is a broad metabolic marker whose reach extends beyond the question of blood sugar alone.

Reading the effort, not just the result

The question that should structure a metabolic panel is not only "is my glucose normal?", but "at what cost is my body keeping it normal, and for how long?" The answer lies less in blood sugar than in the insulin that had to be mobilized to keep it in check.

And as with any metabolic marker, a single value describes a moment; it is the repetition of measurements that traces a direction. Fasting insulin and HOMA-IR followed over time tell you whether compensation is stabilizing or wearing out. That trajectory is what matters.

Frequently asked questions

What is HOMA-IR and what does it measure?#[ + ]

HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is an index calculated from two fasting values: insulin and glucose. It estimates the degree of insulin resistance without requiring a complex test. The usual formula is: fasting insulin (µU/mL) multiplied by fasting glucose (mmol/L), divided by 22.5. The higher the result, the greater the estimated insulin resistance.

Why can fasting glucose stay normal despite insulin resistance?#[ + ]

Because the pancreas compensates. When cells respond less well to insulin, the beta cells secrete more of it to keep glucose within range. Glucose only rises durably once that compensation is exhausted, often after several years. That is why it functions as a lagging indicator.

Is there an optimal fasting insulin or HOMA-IR value?#[ + ]

There is no universal threshold. HOMA-IR reference values vary with population, age, and the insulin assay used by the laboratory. Interpretation therefore favours the trend over time and the overall context of the profile, rather than a single number compared to one fixed norm.

What is the TyG index and when is it useful?#[ + ]

The TyG (triglyceride-glucose) index is a surrogate marker of insulin resistance, calculated from fasting triglycerides and glucose, two parameters found on a standard panel. It is useful when insulin is not measured. Compared to the laboratory reference method (the clamp), it identifies insulin resistance with good sensitivity.

Does insulin resistance only concern diabetes risk?#[ + ]

No. Beyond type 2 diabetes, elevated fasting insulin and elevated HOMA-IR are associated in studies with increased cardiovascular risk, including in people without diabetes. Insulin resistance is a broad metabolic marker whose relevance extends beyond the question of blood sugar alone.

---

References

1. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221 (PubMed).
2. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795 (PubMed).
3. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42(11):1663-1672 (PubMed).
4. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419 (PubMed).
5. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495 (PubMed).
6. Bonora E, Kiechl S, Willeit J, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004;53(7):1782-1789 (PubMed).
7. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304 (PubMed).
8. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347-3351 (PubMed).
9. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952-957 (PubMed).
10. Gast KB, Tjeerdema N, Stijnen T, Smit JWA, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One. 2012;7(12):e52036 (PubMed).